Non-small cell lung cancer: Evaluation of pleural abnormalities on CT scans with 18F FDG PET

Radiology

Volumn 231, Issue 3, 2004, Pages 858-865

  Schaffler, Gottfried J ^a   Wolf, Gerald ^a   Schoellnast, Helmut ^a   Groell, Reinhard ^a   Maier, Alfred ^a   Smolle Jüttner, Freya M ^a   Woltsche, Michael ^b   Fasching, Gerlinde ^a   Nicoletti, Rudolf ^a   Aigner, Reingard M ^a  

^a UNIVERSITY HOSPITAL GRAZ   (Austria)

^b Department of Pulmonology   (Austria)

Author keywords

Lung neoplasms; Lung neoplasms, CT; Lung neoplasms, PET; Pleura, CT; Pleura, neoplasms; Pleura, PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IOPROMIDE; NONIONIC CONTRAST MEDIUM;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG UPTAKE; ELECTRON BEAM TOMOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA CANCER; PLEURA EFFUSION; PLEURA EMPYEMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUNG NEOPLASMS; MALE; MIDDLE AGED; PLEURAL DISEASES; PLEURAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 2442676615     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2313030785     Document Type: Article

References (36)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48:6-29.
2. Pretreatment evaluation of non-small-cell lung cancer. The American Thoracic Society and the European Respiratory Society. Am J Respir Crit Care Med 1997; 156: 320-332.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111:1710-1717.
4. Arenas-Jimenez J, Alonso-Charterina S, Sanchez-Paya J, et al. Evaluation of CT findings for diagnosis of pleural effusions. Eur Radiol 2000; 10:681-690.
5. Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am J Roentgenol 1996; 166:963-968.
6. Kuhlman JE. Complex disease of the pleural space: the 10 questions most frequently asked of the radiologist-new approaches to their answers with CT and MR imaging. RadioGraphics 1997; 17: 1043-1050.
7. Muller NL. Imaging of the pleura. Radiology 1993; 186:297-309.
8. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10:2529-2534.
9. Conti PS, Lilien DL, Hawley K, et al. PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23:717-735.
10. Gupta NC, Frank AR, Dewan NA, et al. Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1992; 184:441-444.
11. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37:943-948.
12. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 17:197-198.
13. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994; 344:1265-1266.
14. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998; 16:1075-1084.
15. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993; 188:487-490.
16. Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994; 58:698-703.
17. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202:441-446.
18. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995; 60:1573-1581.
19. Buchmann I, Guhlmann CA, Elsner K, et al. F-18-FDG PET for primary diagnosis differential diagnosis of pleural processes. Nuklearmedizin 1999; 38:319-322.
20. Bury T, Paulus P, Dowlati A, et al. Evaluation of pleural diseases with FDG-PET imaging: preliminary report. Thorax 1997; 52:187-189.
21. Carretta A, Landoni C, Melloni G, et al. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases: a pilot study. Eur J Cardiothorac Surg 2000; 17:377-383.
22. Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000; 175:245-249.
23. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536.
24. Light RW, Macgregor MI, Luchsinger PC, Ball WCJr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med 1972; 77:507-513.
25. Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771-1776.
26. Tischler ME, Fagan JM. Response to trauma of protein, amino acid, and carbohydrate metabolism in injured and uninjured rat skeletal muscles. Metabolism 1983; 32:853-868.
27. Duque JL, Ramos G, Castrodeza J, et al. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía Torácica. Ann Thorac Surg 1997; 63:944-950.
28. Harpole DH, Liptay MJ, DeCamp MM Jr, et al. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias. Ann Thorac Surg 1996; 61:977-982.
29. Kearney DJ, Lee TH, Reilly JJ, DeCamp MM, Sugarbaker DJ. Assessment of operative risk in patients undergoing lung resection: importance of predicted pulmonary function. Chest 1994; 105:753-759.
30. Pagni S, McKelvey A, Riordan C, Federico JA, Ponn RB. Pulmonary resection for malignancy in the elderly: is age still a risk factor? Eur J Cardiothorac Surg 1998; 14: 40-44.
31. Yano T, Yokoyama H, Fukuyama Y, et al. The current status of postoperative complications and risk factors after a pulmonary resection for primary lung cancer: a multivariate analysis. Eur J Cardiothorac Surg 1997; 11:445-449.
32. Prakash UB, Reiman HM. Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion: analysis of 414 cases. Mayo Clin Proc 1985; 60:158-164.
33. Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975; 67:536-539.
34. Celik M, Halezeroglu S, Senol C, et al. Video-assisted thoracoscopic surgery: experience with 341 cases. Eur J Cardiothorac Surg 1998; 14:113-116.
35. Shah RM, Spirn PW, Salazar AM, et al. Role of thoracoscopy and preoperative localization procedures in the diagnosis and management of pulmonary pathology. Semin Ultrasound CT MR 1995; 16: 371-378.
36. Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36: 1836-1839.